Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic, or 'theranostic,' radiopharmaceuticals. Headquartered in Melbourne, Australia, the company's mission is to become a global leader in radiopharmaceuticals by integrating therapeutic and diagnostic modalities to benefit patients, a precision medicine approach known as "theranostics."

Telix Pharmaceuticals operates through three primary segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, with a focus on oncology and rare diseases. Its key diagnostic product, Illuccix® (Kit for the preparation of Gallium-68 PSMA-11), is an approved imaging agent for prostate cancer in the United States, Europe, and Australia. The company's pipeline includes therapeutic radiopharmaceuticals such as TLX591 for prostate cancer, TLX250 for renal cancer, and TLX101 for glioblastoma.

Led by Managing Director and Group CEO Dr. Christian Behrenbruch, Telix Pharmaceuticals is a commercial-stage company with a strong global presence, including operations in the United States, Europe, Asia-Pacific, Japan, Brazil, and Canada. Recent notable developments include collaborations with EDAP TMS S.A. and Profound Medical Corp. to explore PSMA-PET imaging in prostate cancer treatment, as well as strategic partnerships with Regeneron and United Imaging for theranostics research. The company also announced the acceptance of a Marketing Authorization Application for its glioma imaging candidate, TLX101-Px, in Europe. Telix reported robust financial performance in 2024, with revenue increasing by 56% year-over-year to A$783.2 million.